| 证券代码：603939 | 证券简称：益丰药房 公告编号：2025-072 | | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | 益丰大药房连锁股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的 提示性公告 公司控股股东宁波梅山保税港区厚信创业投资合伙企业（有限合伙）及其一致行动 人宁波梅山保税港区益之丰企业管理合伙企业（有限合伙）、宁波梅山保税港区益仁堂 企业管理合伙企业（有限合伙）、高毅先生保证向本公司提供的信息真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少 | | --- | --- | --- | --- | | 权益变动前合计比例 | 34.85% | | | | 权益变动后合计比例 | 32.85% | | | | 本次变动是否违反已作出的承 | 是□ | 否 | | | 诺、意向、计划 | | | | | 是否触发强制要约收购义务 | 是□ | 否 | | 3.一致行动人信息 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | 控股股东/实际控制人 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-071 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 减持计划实施前股东持股的基本情况 本次减持计划实施前，益丰大药房连锁股份有限公司（以下简称"公司"）控 股股东宁波梅山保税港区厚信创业投资合伙企业（有限合伙）（以下简称"厚信创 投"）持有公司无限售流通股 262,492,776 股，占公司总股本 21.65%。 公司控股股东厚信创投的一致行动人宁波梅山保税港区益之丰企业管理合 伙企业（有限合伙）（以下简称"益之丰"）持有公司无限售流通股 12,692,782 股， 占公司总股本 1.05%。 公司控股股东厚信创投的一致行动人宁波梅山保税港区益仁堂企业管理合 伙企业（有限合伙）（以下简称"益仁堂"）持有公司无限售流通股 5,816,466 股， 占公司总股本 0.48 ...

益丰药房公告，控股股东宁波梅山保税港区厚信创业投资合伙企业（有限合伙）及一致行动人宁波梅山 保税港区益之丰企业管理合伙企业（有限合伙）、宁波梅山保税港区益仁堂企业管理合伙企业（有限合 伙）已于2025年8月5日至2025年8月6日通过大宗交易累计减持2424.82万股，占公司总股本2.00%；其中 厚信创投减持2147.19万股，占1.77%，益之丰减持190.39万股，占0.16%，益仁堂减持87.24万股，占 0.07%，减持计划已实施完毕。 ...

| 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 259.87 | 5945.83 | 22.88 | -6.42 | 摩根大通证券（中国）有限公司 | 中信证券股份有限 | | | | | | 上海银城中路证券营业部 | 公司湖南分公司 | | 190.39 | 4356.12 | 22.88 | -6.42 | 国泰海通证券股份有限公司总部 | 中信证券股份有限 | | | | | | | 公司湖南分公司 | | 184.10 | 4212.21 | 22.88 | -6.42 | 国泰海通证券股份有限公司总部 | 中信证券股份有限 | | | | | | | 公司湖南分公司 | | 150.00 | 3432.00 | 22.88 | -6.42 | 机构专用 | 中信证券股份有限 | | | | | | | 公司湖南分公司 | | 100.00 | 2288.00 | 22.88 ...

8月5日，益丰药房大宗交易成交2352.65万股，成交额5.38亿元，占当日总成交额的85.48%，成交价 22.88元，较市场收盘价24.45元折价6.42%。 | 交易日期 | 证券同核 | 证券代品 | | | 痰交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 群用易不错 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-05 | 草本配送 | 603939 | 22.88 | 204.55 | 8.94 | 机构专用 | 中信证券股份有限 公司减附分公司 | 零 | | 2025-08-05 | 草丰厨房 | 603839 | 22.88 | 203.63 | 8.9 | 机构专用 | 中信证券股份有限 公司湖南分公司 | Ka | | 2025-08-05 | 草本配送 | 603939 | 22.88 | 202.95 | 8.87 | 机构专用 | 中信证券股份有限 公司湖南分公司 | 整 | | 2025-08-05 | 群主经论 | 603939 | 22.88 | 202. ...

Core Viewpoint - The first "Excellent Cases of ESG Practices by Enterprises in the Yangtze River Economic Belt" conference highlighted the importance of ESG (Environmental, Social, and Governance) as a key evaluation system for sustainable development, emphasizing its role in reshaping corporate value and driving industrial transformation [3][4]. Group 1: ESG Policy and Development - Recent years have seen a surge in ESG policies in China, with the Shanghai and Shenzhen Stock Exchanges set to enforce mandatory disclosure of sustainability reports starting April 2024, prioritizing climate change responses [3]. - The Ministry of Finance has integrated climate-related content into its guidelines, aligning with the national "dual carbon" goals [3]. - The State-owned Assets Supervision and Administration Commission has issued guidelines for central enterprises to fulfill social responsibilities, with local state-owned asset management offices also releasing related opinions [3]. Group 2: Corporate Participation and Innovation - Enterprises along the Yangtze River Economic Belt are accelerating their transformation towards a green economy, becoming a key battleground for ecological priority and green development in China [3]. - A diverse group of nearly 100 representatives from central and local state-owned enterprises, as well as large private companies, gathered to discuss innovative approaches to sustainable development and the integration of ESG principles [4]. - The conference featured 45 companies recognized for their outstanding ESG practices in 2024, showcasing their innovative measures through video presentations [5].

Core Viewpoint - The company has announced an extension of the completion date for its fundraising investment project, the "Yifeng Digital Platform Upgrade Project," from July 31, 2025, to December 31, 2025, without changing the project implementation subject, method, total investment amount, or purpose [2][5][6]. Fundraising Basic Information - The company issued 17,974,320 convertible bonds at a face value of RMB 100 each, raising a total of RMB 1,797.432 million. After deducting underwriting and sponsorship fees, the net amount raised was RMB 1,780.932 million [3][4]. Fundraising Usage Status - As of June 30, 2025, the company has invested RMB 73.621 million in the "Yifeng Digital Platform Upgrade Project," achieving an investment progress of 91.29% against a planned total investment of RMB 80.642 million [4]. Reasons for Project Delay - The delay in the "Digital Project" is due to the complexity of integrating multiple systems (product, logistics, finance, and human resources), which has led to challenges in platform integration and promotion. Additionally, some expenses related to personnel salaries and social insurance cannot be paid directly from the fundraising account, necessitating the use of self-owned funds initially [5][6]. Impact of Project Delay - The project delay is a prudent decision based on the actual implementation situation and will not adversely affect the company's normal operations or harm the interests of shareholders, particularly minority shareholders. The decision aligns with the company's long-term development plan [6][8]. Review Procedures and Opinions - The board of directors and the supervisory board approved the extension of the project completion date during meetings held on July 30, 2025. The supervisory board expressed agreement with the decision, confirming compliance with relevant laws and regulations [7][8][9].

Core Points - The board of directors of Yifeng Pharmacy held its 19th meeting of the 5th session on July 30, 2025, with all 9 directors present, and the meeting was conducted in accordance with legal and regulatory requirements [1][4] - The board approved several key proposals, including the cancellation of the supervisory board and amendments to the company's articles of association, which will be submitted for shareholder approval [2][5] - The board also approved the extension of the completion date for the "Yifeng Digital Platform Upgrade Project" from July 31, 2025, to December 31, 2025, without changing the project implementation subject, method, total amount of raised funds, or purpose [3][4] - A proposal was made to use up to 7.05 million yuan of the company's own funds to cover certain costs related to the digital platform upgrade project, with plans to replace these funds with equivalent amounts from the raised funds [3][4] - The company will hold its second extraordinary general meeting of 2025 on August 25, 2025, at 14:30, in Changsha, Hunan Province, with the board authorized to handle related matters [5]

证券代码：603939 证券简称：益丰药房 公告编号：2025-066 债券代码：113682 债券简称：益丰转债 益丰大药房连锁股份有限公司 （1）《关于取消监事会并修订 <公司章程> 的议案》 本议案尚需提交公司股东会审议。 具体内容详见公司同日于上海证券交易所网站（http://www.sse.com.cn）与 公司指定的信息披露媒体上披露的《关于取消监事会并修订 <公司章程> 及修订、 制定公司部分制度的公告》。 表决结果：3 票同意，0 票反对，0 票弃权。 第五届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 益丰大药房连锁股份有限公司（以下简称"公司"）于 2025 年 7 月 25 日以 电子邮件方式发出第五届监事会第十三次会议通知，会议于 2025 年 7 月 30 日在 湖南省长沙市金洲大道 68 号益丰医药物流园五楼会议室召开，应参加表决的监 事 3 人，实际参加表决的监事 3 人，会议以现场方式召开，本次会议的召集、召 开和表决程序符合有关法律、法规和《 ...

证券代码：603939 证券简称：益丰药房 公告编号：2025-070 债券代码：113682 债券简称：益丰转债 益丰大药房连锁股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (二) 股东会召集人：董事会 召开的日期时间：2025 年 8 月 25 日 14 点 30 分 召开地点：湖南省长沙市金洲大道 68 号益丰医药物流园三楼会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 8 月 25 日 至2025 年 8 月 25 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务 ...